Member Info for Kaneonaim

IB StoneChecker is an innovative software tool to aid clinical decisions by providing information about a patient’s kidney stone. The tool provides a semi-automated assessment with useful clinical metrics using the patient’s non-contrast CT scans. #kidneystones

https://twitter.com/IQAI_IB/status/1567191213522190336

Great news! "I am a participant in this trial. It has been a very positive experience so far."

A facebook comment by a participant in theIB Phase I Trial (Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma). http://clinicaltrials.gov NCT04319276

Try this One

https://fda.report/Company/Imaging-Biometrics-L-L-C

Lol!

Imaging Biometics, IQ-AI’s principal investment, recently received a strong endorsement from a leading pharmaceutical company, Bayer AG. The Company’s IB Clinic platform has been chosen to debut in the launch of Bayer’s entrance into artificial intelligence-enabled radiology applications. Bayer’s Calantic platform features only nine products from seven independent companies, which have agreed to partner with Bayer in what is arguably a bold move in the fast-growing radiology applications market. We believe inclusion in this small group speaks well to the technological strength in IB Clinic and the capacity of Imaging Biometrics to support customers. It is logical that Bayer would only risk its world class reputation with strong partners who can help win and retain customers.

We are steadfast in our interest in IQ-AI Ltd. and reiterate our Speculative Buy rating of IQAI.L with a target price of 6.50 GBp. Despite an uptick in new interest in the shares, the stock price has traded downward in sympathy with the broader U.S. equity market. This is unfortunate, in our view, given that worries about inflation that have weighed on investor sentiment apply only tangentially to IQ-AI and its channel partners. We believe hospitals and clinics making capital investments in efficiency-creating products are not likely to alter decisions based on the prospect of inflation rates.

https://crystalequityresearch.com/wp-content/uploads/2022/07/IQAI-IQAIF-Update-Report-July-29-2022.pdf

“the current MC is still factoring in success here, of white to date, there hasn't been any!”

You are a muppet!! Their software is being used by some of the biggest cancer/treatment institutions in the USA. How can you sit there and say they’ve had no success are you really that delusional/thick?

IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF), a developer and manufacturer of medical image processing platforms that have led to effective therapeutic strategies for brain tumor and other patients, today announced the University of Texas MD Anderson Cancer Center (Houston, TX) is the latest brain cancer center to purchase an annual subscription of IB Clinic software. IB Clinic is an automated processing application that generates quantitative magnetic resonance (MR) perfusion images and other maps useful in assessing brain tumors and monitoring treatment.

Ranked as the #1 cancer center in the USA by U.S. News & World Report, MD Anderson Cancer Center is renowned for excellence in brain cancer care. Its specialized and multidisciplinary teams use cutting edge technologies to offer patients personalized care in attempt to improve outcomes.

IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF), a developer of medical image processing platforms that have led to effective therapeutic strategies for brain tumor and other patients, and St. Jude Children's Hospital (Memphis, TN), have entered into a Data Use Agreement. The Agreement is a specific type of agreement required under the Health Insurance Portability and Accountability Act (HIPPA) Privacy Rule. It will provide Imaging Biometrics (IB) access to paediatric imaging datasets for use in the development of its patented, artificial intelligence (AI) technology, IB Zero G.

St. Jude Children's Hospital is the only National Cancer Institute (NCI)-designated Comprehensive Care Centre devoted solely to children. It has received the NCI's highest ranking of "exceptional" and has treated children from all 50 US states and from around the world.

Imaging Biometrics®, LLC ("IB"), a subsidiary of IQ-AI Limited (LON:IQAI), announced today that Los Angeles County Hospital (LAC) has purchased IB Clinic. Following the recent installation at the Keck Medical Center of USC, the purchase further extends IB's exclusive quantitative imaging capabilities throughout the entire USC and LA County Hospital network; the hub in the County-run healthcare system which serves over 10 million residents.

Imaging Biometrics®, LLC ("IB"), a subsidiary of IQ-AI Limited (LON:IQAI), is pleased to announce that the Montgomery Cancer Center (Montgomery, Alabama, USA), has purchased IB Clinic. The Montgomery Cancer Center, one of the largest freestanding centers in the USA, will now be able to automatically generate quantitative parameters using IB's standardised brain tumour imaging protocol for the benefit of patients.

These are just a few examples I chose to make you look stupid.

GLA try to ignore the idiots!!

It’s comical to read the rubbish it’s posting, now talking about 150billion shares lol!

Muppet!!

All resolutions passed

Check out this very early stage beta test of the Tintra Metaverse Bridge from a few days ago. What you are seeing here is a portal to Decentraland being dropped right in the middle of our office. Kinda cool! #tintra #web3 #ai #metaverse

https://twitter.com/tintraplc/status/1551924597938855938

In addition, a major pharmaceutical company is working with yet another partner to develop their own custom platform which includes 3rd party artificial intelligence (AI) solutions. This company was very selective in choosing which 3rd party applications would participate in early launch activity in the USA and in Europe. IB software was one of the few selected partners given our unique and proven capabilities. This is highly encouraging as we expect an accelerated penetration of our solution in the global medical imaging market with the backing and broad outreach of a multibillion-dollar organization.

It’s at the beginning

IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI), is pleased to announce that its medical imaging analysis software, IB Clinic®, is now available via the newly launched Bayer Calantic platform. This latest distribution partnership continues IQ-AI's strategy of making IB Clinic's unique quantitative solutions accessible through widespread, global networks and marks the culmination of previously announced integration and validations efforts initiated in 2021.

Inittowinit

Muppet!!

Trek there is no nomad to advise this is not aim!

Yes now it’s there for all to see hopefully onwards and upwards!! GLA!

Just posted

Date Time Trade Prc Volume Buy/Sell Value
07-Jul-22 11:47:23 65.00 203,750 Unknown* £132.44k

Iqai

Over the next year there are several potential catalysts for a favorable shift in sentiment.
• First, we expect the Company to report favorable comparisons in sales with its half year and full year reports for the year 2022. The reports should confirm expectations for growth as well as the Company’s competitive position. The Company has typically published its half year report in August and full year report in May.
• Second, by the end of 2022, there is likely to be a public announcement of results for IB’s current Phase I clinical trial focused gallium maltolate as a cancer treatment. Subsequently, it is possible there could be some action by the U.S. FDA such as approval for additional Phase I trials. Such action would provide further assurance that the GaM candidate ‘has legs.’
• Third, there is potential to receive anecdotes related to the Company’s market relationship with Blackford Analytics. We view this pact as a key driver of future market penetration, representing upside potential to our sales estimates and therefore valuation of IQAI.

: “IB has recently submitted a 501(k) application to the U.S. FDA,The application claims IB Zero G is safe, effective and substantially equivalent to a legally marketed device. IB leadership expects a favorable response within three months, enabling commercial introduction of IB Zero G before the end of 2022.”

Bayer Launches Calantic™ Digital Solutions to help Address Radiology Industry Challenges
New platform includes suite of apps to help manage radiologist workload, help with lesion detection and patient management

Launch strategically expands Bayer’s strong radiology portfolio
Vendor-neutral, cloud-based marketplace delivers access to digital and artificial intelligence (AI) applications throughout the medical imaging workflow
June 28, 2022 08:04 AM Eastern Daylight Time
PITTSBURGH--(BUSINESS WIRE)--Bayer today unveiled Calantic™ Digital Solutions, a new cloud-hosted platform delivering access to digital applications, including AI-enabled programs, for medical imaging. The offering contains tools to help triage critical patient findings for expedited review, improve lesion detection and automate tasks. With this launch, Bayer expands its radiology portfolio beyond contrast media, devices, software and services, with the ultimate goal of supporting healthcare professionals to aid in the detection of disease patterns throughout the patient’s journey.

“AI has the potential to transform healthcare, and, particularly in medical imaging, it can turn the growing amounts of data into value-adding insights to support radiologists and their teams in their decision-making”

https://www.businesswire.com/news/home/20220627005822/en/Bayer-Launches-Calantic%E2%84%A2-Digital-Solutions-to-help-Address-Radiology-Industry-Challenges

@IQAI_IB
's lesion quantification and other IB solutions are available via the Calantic Digital platform. https://calantic.com/neuro-service-line-apps-available-us

https://twitter.com/IQAI_IB/status/1545388379050852353

Nominated Advisor (NOMAD)?
A nominated advisor (NOMAD) is a financial services firm that assists with listing a company on the Alternative Investment Market (AIM) of the London Stock Exchange (LSE). The Alternative Investment Market is a specialized unit of the LSE catering to smaller, more risky companies.

The LSE requires that a company seeking a listing on AIM have a NOMAD, which the LSE itself must approve to carry out the functions. Once listed on the AIM, the NOMAD oversees the company and ensures it follows regulations. NOMADs are thus seen as the regulatory system for the less-stringent AIM market and are tasked with advising companies both pre-IPO and after listing.

This is listed on the main market not aim. So directors are responsible for the information in rns. See bottom disclaimer

“The Directors of the Company accept responsibility for the contents of this announcement.”

Interesting study showing clinical utility of DWI-MRI.
@IQAI_IB
's IB Diffusion automatically generates ADC, extrapolated b-value, and other DWI parameters.

DWI-MRI predicts whether women's DCIS will upstage after surgery via
@AuntMinnie
https://auntminnie.com/index.aspx?sec=sup&sub=wom&pag=dis&ItemID=136337&wf=11873&wf=6524…
@BreastImaging

https://twitter.com/IQAI_IB/status/1545027119356551169